Maravai LifeSciences (MRVI) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on May 26, 2026, with shareholders able to vote on key proposals and submit questions online.

• Shareholders of record as of March 27, 2026, are entitled to vote on the election of directors, auditor ratification, executive compensation, and other business.

• The Board recommends voting in favor of all proposals, including director nominees, auditor ratification, and executive compensation.

Voting matters and shareholder proposals

• Shareholders will vote on electing three directors, ratifying Deloitte & Touche LLP as auditor, and approving executive compensation on an advisory basis.

• Shareholder proposals for the 2027 meeting must be received by December 25, 2026, for proxy inclusion, and director nominations must be submitted between January 26 and February 25, 2027.

• The Board recommends voting FOR all proposals.

Board of directors and corporate governance

• The Board is divided into three classes, with eight directors post-2025, and nominees serve three-year terms.

• GTCR, as controlling shareholder, has significant nomination rights and Board influence.

• Four directors are independent per Nasdaq standards; the company relies on controlled company exemptions for some governance requirements.

• Board committees include Audit, Compensation and Leadership Development, and Nominating, Governance and Risk, each with defined responsibilities.

• The Chairman is independent and separate from the CEO.